Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 02/29/24
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024GlobeNewsWire • 02/22/24
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial OfficerGlobeNewsWire • 11/16/23
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 11/02/23
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023GlobeNewsWire • 10/26/23
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"GlobeNewsWire • 08/16/23
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational UpdateGlobeNewsWire • 08/03/23
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023GlobeNewsWire • 07/27/23
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive OfficerGlobeNewsWire • 06/27/23
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/31/23
Chimerix's trial treating pediatric brain tumors has a 'relatively high' chance of successProactive Investors • 05/25/23